.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Medtronic
Chinese Patent Office
Baxter
Express Scripts
Cerilliant
US Army
Accenture
UBS
Covington

Generated: December 18, 2017

DrugPatentWatch Database Preview

Fosamprenavir calcium - Generic Drug Details

« Back to Dashboard

What are the generic sources for fosamprenavir calcium and what is the scope of fosamprenavir calcium freedom to operate?

Fosamprenavir calcium
is the generic ingredient in two branded drugs marketed by Viiv Hlthcare and Mylan Pharms Inc, and is included in three NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fosamprenavir calcium has one hundred and twenty patent family members in fifty-three countries and eleven supplementary protection certificates in ten countries.

There are four drug master file entries for fosamprenavir calcium. Five suppliers are listed for this compound. There is one tentative approval for this compound.

Tentative approvals for FOSAMPRENAVIR CALCIUM

Applicant Application No. Strength Dosage Form
u► Subscribe700MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv HlthcareLEXIVAfosamprenavir calciumTABLET;ORAL021548-001Oct 20, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Viiv HlthcareLEXIVAfosamprenavir calciumTABLET;ORAL021548-001Oct 20, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Mylan Pharms IncFOSAMPRENAVIR CALCIUMfosamprenavir calciumTABLET;ORAL204060-001Apr 15, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Viiv HlthcareLEXIVAfosamprenavir calciumSUSPENSION;ORAL022116-001Jun 14, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fosamprenavir calcium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,559,137 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors► Subscribe
7,592,368Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors► Subscribe
6,838,474 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fosamprenavir calcium

Country Document Number Estimated Expiration
New Zealand505776► Subscribe
Brazil9912156► Subscribe
Estonia04466► Subscribe
Poland345620► Subscribe
Indonesia24962► Subscribe
Hungary229700► Subscribe
Bulgaria104631► Subscribe
Ukraine72733► Subscribe
New Zealand509291► Subscribe
South Korea100520737► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FOSAMPRENAVIR CALCIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4Finland► Subscribe
2008 00027Denmark► Subscribe
2008006,C0933372Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C/GB08/018United Kingdom► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0339Netherlands► Subscribe300339, 20180310, EXPIRES: 20190711
426Luxembourg► Subscribe91426, EXPIRES: 20190712
0933372/01Switzerland► SubscribePRODUCT NAME: FOSAMPRENAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56706 17.03.2005
C0015France► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIQUE; REG. NO/DATE: EU/1/07/282/001-002 20040712
C012/2008Ireland► SubscribeSPC012/2008: 20091119, EXPIRES: 20190711
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Accenture
Queensland Health
Colorcon
Federal Trade Commission
Chubb
Cantor Fitzgerald
AstraZeneca
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot